Zealand Pharma and Roche Report Phase 2 Petrelintide Data at EASD Milan
Zealand Pharma and Roche released fuller Phase 2 obesity data for their partnered amylin analog, petrelintide, at the European Association for the Study of Diabetes annual meeting in Milan, showing that the drug candidate produced its best weight-loss result at the middle dose tested, biotech-insider.com reported. The presentation followed initial topline numbers from the Zupreme-1 and Zupreme-2 trials. Zealand reported mean weight loss on petrelintide of up to 9.2% at Week 28 in the Zupreme-2 trial of people with Type 2 diabetes, compared to 2% for placebo, fiercebiotech.com reported.
Dose-Response Curves and Weight Loss Results in Midphase Trials
The Milan presentation revealed that petrelintide reached its peak weight-loss efficacy at the middle dose rather than the highest dose tested. In early obesity trials, developers typically look for weight loss to increase steadily alongside rising doses to confirm the mechanism and establish headroom for Phase 3 testing. When a middle dose outperforms a high dose, analysts generally attribute the pattern either to tolerability issues prompting patients to reduce or stop doses, or to a biological plateau. Zealand and Roche reported that petrelintide’s tolerability profile remained largely comparable to placebo, with 1.9% of participants discontinuing treatment due to gastrointestinal adverse events in the drug arms, compared to 1.7% in the placebo arm, fiercebiotech.com reported.
Blood Sugar Reductions and Cross-Trial Comparisons with Eli Lilly
Cross-trial comparisons showed petrelintide trailing rival treatments in blood sugar control. At Week 28 in the Zupreme-2 trial, the mean decline in HbA1c on petrelintide was 0.65%, falling short of competing incretin therapies where reductions range from 1.3% to 2.1%, fiercebiotech.com reported. William Blair analysts noted that petrelintide’s 7.2% placebo-adjusted weight loss matched results reported by Eli Lilly for its competing amylin receptor agonist, eloralintide, in a phase 2 trial. However, Eli Lilly’s established portfolio in metabolic medicine continues to set the benchmark against which newer amylin candidates are measured, biotech-insider.com reported.
Strategic Positioning for Roche and Zealand Pharma Ahead of Phase 3
Roche acquired its partnership in the petrelintide program to establish a presence in the competitive obesity treatment market, where GLP-1 receptor agonists currently dominate. Following the release of the midphase data, Roche ADR shares closed down 1.98% at 53.37 on September 29, 2026, biotech-insider.com reported. William Blair analysts suggested that petrelintide will likely find its primary clinical utility in the maintenance setting and the overweight segment, where chronic use demands a therapeutic intervention with placebo-like tolerability, fiercebiotech.com reported. Meanwhile, Roche has initiated a trio of Phase 3 trials for petrelintide, including the Zupreme-4 study, which is actively recruiting 600 participants with overweight or obesity and Type 2 diabetes, fiercebiotech.com reported.
Frequently Asked Questions About the Petrelintide Phase 2 Data
What is petrelintide and how does it work?
Petrelintide is an amylin analog developed jointly by Zealand Pharma and Roche. Amylin is a hormone released alongside insulin that helps signal fullness and slows stomach emptying, offering an alternative appetite-suppression mechanism to GLP-1 receptor agonists.
What were the exact weight-loss figures reported in the Zupreme-2 trial?
Participants in the Zupreme-2 trial experienced a mean weight loss of up to 9.2% at Week 28 when treated with petrelintide, compared to a 2% reduction observed in the placebo group, fiercebiotech.com reported.
How did petrelintide’s discontinuation rate compare to placebo?
Discontinuation rates due to gastrointestinal adverse events were 1.9% among participants receiving petrelintide and 1.7% among those receiving the placebo, according to data reported by Zealand and cited by fiercebiotech.com.
What are the next clinical steps for the petrelintide development program?
Roche has initiated a trio of Phase 3 clinical trials for petrelintide, a central program that includes the Zupreme-4 trial recruiting 600 individuals with overweight or obesity and Type 2 diabetes, fiercebiotech.com reported.
Worth a look